Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancrease MT in CF-dependent EPI
NCT00662675Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2008
- Primary completion
- Feb 2009
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing Pancrease MT with Placebo (2 arms). Primary endpoint: Change in Coefficient of Fat Absorption at 72 hours. Started Aug 2008; status: completed.
02
Drugs
Pancrease MT
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00662675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662675.